Factors associated with outcomes of second-line treatment for EGFR-mutant non-small-cell lung cancer patients after progression on first- or second-generation EGFR-tyrosine kinase inhibitor treatment

Overview of attention for article published in Frontiers in oncology, June 2023

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Good Attention Score compared to outputs of the same age and source (69th percentile)

Mentioned by

twitter: 2 X users

Readers on

mendeley: 1 Mendeley

Summary X

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 6,921 followers.

RT @FrontOncology: New research: Factors associated with outcomes of second-line treatment for EGFR-mutant non-small-cell lung cancer patie…

30 Jun 2023

Reply Repost Favourite

New research: Factors associated with outcomes of second-line treatment for EGFR-mutant non-small-cell lung cancer patients after progression on first- or second-generation EGFR-tyrosine kinase inhibitor treatment: Purpose Epidermal growth… #oncology http

30 Jun 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.